Study to Evaluate the Efficacy and Safety of AstroStem-V in Treatment of COVID-19 Pneumonia

Nature Cell

Status and phase

Enrolling

Phase 2

Phase 1

Conditions

Covid19 Pneumonia

Treatments

Drug: AstroStem-V

Study type

Interventional

Funder types

Industry

Identifiers

NCT04527224

ASVP1N2A-US

Details and patient eligibility

About

This study is an open-label, single-arm study to evaluate the safety and efficacy of Astrostem-V, allogenic adipose tissue derived mesenchymal stem cells (AdMSC), in patients with COVID-19 pneumonia. After each subject completes 12-Weeks visit (Visit 12) and the data management team confirms all individual data have no issue, the individual database will be locked and the blinding will be open for the statistical analysis.

Enrollment

10 estimated patients

Sex

All

Ages

19 to 80 years old

Volunteers

No Healthy Volunteers

Inclusion criteria

Adults aged 19 to 80 years at the time of signing the written consent form
Subjects diagnosed with pneumonia by radiologic examination (Chest X-ray or CT) at screening and baseline
subject who has moderate COVID-19 disease:
- Subjects have laboratory-confirmed SARS-CoV-2 infection within 28 days from screening by authorized a reverse-transcription polymerase chain reaction (RT-PCR) or equivalent testing at baseline
- A subject who has symptoms of moderate illness with COVID-19, which could include any symptom of mild illness or shortness of breath with exertion
- A subject who has clinical signs suggestive of moderate illness with COVID-19, such as respiratory rate ≤ 20 breaths per minute, SpO2 ≥ 93% on room air at sea level, heart rate ≤ 90 beats per minute
- No clinical signs indicative of severe COVID-19 disease severity
Subjects voluntarily participate in the clinical trial with written informed consent

Exclusion criteria

Subjects who have pulmonary disease except COVID-19 pneumonia
SpO2 ≤ 93%
Subjects who have uncontrolled shock
Subjects diagnosed with COVID-19 with CPR or requires treatment of Extra Corporeal Membrane Oxygenation (ECMO)
Subjects with an irreversible brain lesion or medical history of malignant tumors
Subjects treated for heart disease within 3 months prior to screening
Subjects who are receiving immunosuppressant therapy for transplantation or who are taking immunosuppressive drugs such as steroids, TNF-alpha inhibitors
Subject treated with stem cells.
Subjects with end-stage renal failure who need renal replacement therapy or cirrhosis patients with complications
Subjects who have an average life expectancy to be less than 2 months due to the underlying disease
Subjects who have history of thromboembolism or pulmonary arterial hypertension
Subjects who currently have positive HIV test results
Pregnant or breast-feeding women
Subjects with pregnancy planned during clinical trials. Women or men of childbearing age who do not agree to maintain contraception by choosing, or who do not agree to use the appropriate method of contraception
- suitable contraceptive methods: condom, sponge, foam, gel, diaphragm for contraception, intrauterine device, etc. Periodic abstinence (eg, calendar method, ovulation method, symptom body temperature method, post ovulation method) and restraint is not considered an accepted method of contraception, and hormonal contraceptives are not allowed. However, women having no potential are pregnancy due to menopause (amenorrhea more than 12 months after the last menstruation) or surgical infertility is possible to participate in the study only the pregnancy test is negative
Subjects who administered other investigational products within 12 weeks prior to IP administration
Subject who the principal investigator considers inappropriate for the study due to any other reasons than those listed above
Subjects who cannot tolerate aspirin